Сardioprotective agents with biaromatic structure. Part 6. Beta blockers
https://doi.org/10.37489/2587-7836-2023-3-3-11
Abstract
β-Blockers are one of the oldest classes of cardioprotectors used in the treatment of cardiovascular diseases. They reduce the heart rate, have a hypotensive effect, inhibit myocardial contractility and have antiarrhythmic properties. In the series of biaromatic compounds with a linear linker, there is a quite large group of β-blockers, which in addition to two aromatic nuclei contain a 1,2-dihydroxy-3-aminopropane fragment in the linker, that is the key for the presence of β-blocking activity. Among the compounds of this group are widely used drugs nebivolol and carvedilol, which are used in the treatment of chronic heart failure and arterial hypertension.
About the Author
G. V. Mokrov
FSBI “Zakusov Institute of Pharmacology”
Russian Federation
Russian Federation
Grigory V. Mokrov - PhD, Cand. Chemical Sci., Leading researcher of the fine organic synthesis laboratory at the drug chemistry department
Moscow
References
1. Fisker FY, Grimm D, Wehland M. Third-generation beta-adrenoceptor antagonists in the treatment of hypertension and heart failure. Basic Clin Pharmacol Toxicol. 2015 Jul;117(1):5–14. DOI: 10.1111/bcpt.12396.
2. Velmurugan BK, Baskaran R, Huang CY. Detailed insight on β-adrenoceptors as therapeutic targets. Biomed Pharmacother. 2019 Sep;117:109039. DOI: 10.1016/j.biopha.2019.109039.
3. Black JW, Crowther AF, ShankS RG, et al. A NEW ADRENERGIC BETARECEPTOR ANTAGONIST. Lancet. 1964 May 16;1(7342):1080–1081. DOI: 10.1016/s0140-6736(64)91275-9.
4. Baker JG, Gardiner SM, Woolard J, et al. Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. FASEB J. 2017;31(7):3150–3166. DOI: 10.1096/FJ.201601305R
5. Mokrov GV. Сardioprotective agents with biaromatic structure. Part 1. Calcium channel blockers. Pharmacokinetics and Pharmacodynamics. 2021;(4):3–17. (In Russ.). DOI: 10.37489/2587-7836-2021-4-3-17.
6. Mokrov GV. Сardioprotective agents with biaromatic structure. Part 2. HCN channel blockers. Pharmacokinetics and Pharmacodynamics. 2022;(2):3–10. (In Russ.). DOI: 10.37489/2587-7836-2022-2-03-10.
7. Mokrov GV. Сardioprotective agents with biaromatic structure. Part 3. Sodium channel blockers. Pharmacokinetics and Pharmacodynamics. 2022;(3):3–9. (In Russ.). DOI:10.37489/2587-7836-2022-3-3-9
8. Mokrov GV. Сardioprotective agents with biaromatic structure. Part 4. Potassium hERG channels blockers and modulators. Pharmacokinetics and Pharmacodynamics. 2022;(4):3–19. (In Russ.). DOI:10.37489/2587-7836-2022-4-3-19.
9. Mokrov GV. Сardioprotective agents with biaromatic structure. Part 5. Potassium Kv1.5-channels blockers. Pharmacokinetics and Pharmacodynamics. 2023;(2):3–13. (In Russ.). DOI:10.37489/2587-7836-2023-2-3-13.
10. Howe R, Rao BS, Chodnekar MS. Beta-adrenergic blocking agents. VII. 2-(1,4-benzodioxanyl) and 2-chromanyl analogs of pronethalol (2-isopropylamino-1-(2-naphthyl)ethanol). J Med Chem. 1970 Mar;13(2): 169–176. DOI: 10.1021/jm00296a001.
11. Van Lommen GRE, De Bruyn MFL, Schroven MFJ. US Patent 4654362 A. Published online October 12, 1984.
12. Van de Water A, Janssens W, Van Neuten J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol. 1988 May;11(5):552–563. DOI: 10.1097/00005344-198805000-00007.
13. Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacol Res. 1998 Dec;38(6):419-431. DOI: 10.1006/phrs.1998.0387. PMID: 9990650.
14. Weiss R. Nebivolol: A Novel Beta-Blocker with Nitric Oxide-Induced Vasodilatation. Vasc Health Risk Manag. 2006;2(3):303. DOI: 10.2147/VHRM.2006.2.3.303.
15. Olawi N, Krüger M, Grimm D, et al. Nebivolol in the treatment of arterial hypertension. Basic Clin Pharmacol Toxicol. 2019 Sep;125(3):189-201. DOI: 10.1111/bcpt.13248.
16. Augstein J, Cox DA, Ham AL, et al. Beta-adrenoceptor blocking agents. 1. Cardioselective 1-aryloxy-3-(aryloxyalkylamino)propan-2-ols. J Med Chem. 1973 Nov;16(11):1245-1251. DOI: 10.1021/jm00269a007.
17. Hoefle ML, Hastings SG, Meyer RF, et al. Cardioselective betaadrenergic blocking agents. 1. 1-((3,4-Dimethoxyphenethyl)amino)-3-aryloxy-2-propanols. J Med Chem. 1975 Feb;18(2):148-152. DOI: 10.1021/jm00236a007.
18. Dukes ID, Vaughan Williams EM. Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile. Br J Pharmacol. 1985 Feb;84(2):365-380. DOI: 10.1111/j.1476-5381.1985.tb12921.x.
19. Frishman WH, Goldberg RJ, Benfield P. Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. Drugs. 1988 Jan;35(1):1–21. DOI: 10.2165/00003495-198835010-00001.
20. Rodrigues EA, Lawrence JD, Dasgupta P, et al. Comparison of bevantolol and atenolol in chronic stable angina. Am J Cardiol. 1988 Jun 1;61(15):1204–1209. DOI: 10.1016/0002-9149(88)91155-1.
21. Warner-lambert pipeline narrowed to 40 active research compounds: accupril (quinapril) nda submitted jan. 25; $80 Mil. budgetted for c-v work in 1989 : Pink Sheet. Published 1989. Accessed October 28, 2021. https://pink.pharmaintelligence.informa.com/ps015015/warnerlambert-pipelinenarrowed-to-40-active-research-compounds-accupril-quinapril-ndasubmitted-jan-25-80-mil-budgetted-for-cv-work-in-1989
22. Kreighbaum WE, Matier WL, Dennis RD, et al. Antihypertensive indole derivatives of phenoxypropanolamines with beta-adrenergic receptor antagonist and vasodilating activity. J Med Chem. 1980 Mar;23(3):285–289. DOI: 10.1021/jm00177a015.
23. Hershberger RE, Wynn JR, Sundberg L, Bristow MR. Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol. 1990;15(6):959–967. DOI: 10.1097/00005344-199006000-00014.
24. Eichhorn EJ. Effects of bucindolol in heart failure. Am J Cardiol. 1993 Mar 25;71(9):65C-70C. DOI: 10.1016/0002-9149(93)90089-u.
25. FDA rejects bucindolol and questions trial integrity. Published 2009. Accessed October 28, 2021. http://www.cardiobrief.org/2009/06/02/fdarejects-bucindolol-and-questions-trial-integrity/
26. Wiedemann F, Kampe W, Thiel M, Sponer G, Roesch E, Dietmann K. US Patent 4503067. Published online 1985. https://www.uspto.gov/web/offices/com/sol/foia/comm/pte/4503067.pdf
27. Ruffolo RR, Gellai M, Hieble JP, et al. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38 Suppl 2:S82-8. doi: 10.1007/BF01409471.
28. Mctavish D, Campoli-Richards D, Sorkin EM, Doggrell SA. Carvedilol A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy. Drugs. 1993;45(2):232–258. DOI: 10.2165/00003495-199345020-00006.
29. Book WM. Carvedilol: A Nonselective β Blocking Agent With Antioxidant Properties. Congest Hear Fail. 2002;8(3):173–177, 190. DOI: 10.1111/j.1527-5299.2002.00718.x.
30. Fuhrer W, Ostermayer F, Zimmermann M. US Patent 4559354. Published online 1985.
31. Dooley DJ, Bittiger H, Reymann NC. CGP 20712 A: a useful tool for quantitating β1- and β2-adrenoceptors. Eur J Pharmacol. 1986;130(1-2): 137–139. DOI: 10.1016/0014-2999(86)90193-7.
32. Louis WJ, Berthold R, Stoll A. US Patent 4816604. Published online 1989.
33. Louis SNS, Nero TL, Iakovidis D, et al. LK 204–545, a highly selective β1-adrenoceptor antagonist at human β-adrenoceptors. Eur J Pharmacol. 1999;367(2-3):431-5. doi: 10.1016/S0014-2999(99)00019-9.
34. Louis WJ, Jackman GP, Iakovidis D, Louis SN, Drummer OH. WO Patent 97/13744A1. Published online 1997. Accessed October 28, 2021. https://patentimages.storage.googleapis.com/cf/b4/ed/cdbb8d5f1d23dd/WO1997013744A1.pdf
35. Jackman GP, Iakovidis D, Nero TL, et al. Synthesis, β-adrenoceptor pharmacology and toxicology of S-(−)-1-(4-(2-ethoxyethoxy)phenoxy)-2-hydroxy-3-(2-(3,4-dimethoxyphenyl)ethylamino)propane hydrochloride, a short acting β1-specific antagonist. Eur J Med Chem. 2002;37(9):731-41. DOI: 10.1016/S0223-5234(02)01399-5.
36. Mistry S, Daras E, Fromont C, et al. WO Patent 2021/004549 A1. Published online 2012.
37. Mistry SN, Baker JG, Fischer PM, et al. Synthesis and in Vitro and in Vivo Characterization of Highly β1-Selective β-Adrenoceptor Partial Agonists. J Med Chem. 2013;56(10):3852–3865. DOI: 10.1021/jm400348g.
38. Baker JG, Fischer PM, Fromont C, et al. WO Patent 2021/104659 A1. Published online 2012.
39. Ghabbour HA, El-Bendary ER, El-Ashmawy MB, El-Kerdawy MM. Synthesis, Docking Study and β-Adrenoceptor Activity of Some New Oxime Ether Derivatives. Molecules. 2014;19(3):3417–3435. DOI: 10.3390/molecules19033417.
Review
For citations:
Mokrov G.V. Сardioprotective agents with biaromatic structure. Part 6. Beta blockers. Pharmacokinetics and Pharmacodynamics. 2023;(3):3-11. (In Russ.) https://doi.org/10.37489/2587-7836-2023-3-3-11
Views:
292
Email this article 